Phalguni Deswal, Author at Clinical Trials Arena https://www.clinicaltrialsarena.com/author/phalgunideswal/ Hard data and deep insights on clinical trials strategy & operations Fri, 08 Nov 2024 11:44:34 +0000 en-US hourly 1 https://wordpress.org/?v=6.6.2 https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/01/cropped-Clinical-Trials-Arena-32x32.png Phalguni Deswal, Author at Clinical Trials Arena https://www.clinicaltrialsarena.com/author/phalgunideswal/ 32 32 AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trial https://www.clinicaltrialsarena.com/news/astrazeneca-and-amgens-tezspire-succeeds-in-phase-iii-nasal-polyps-trial/ Fri, 08 Nov 2024 11:44:06 +0000 https://www.clinicaltrialsarena.com/news/astrazeneca-and-amgens-tezspire-succeeds-in-phase-iii-nasal-polyps-trial/ The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with nasal polyps.

The post AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trial appeared first on Clinical Trials Arena.

]]> The post AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trial appeared first on Clinical Trials Arena.

]]> Castle boasts melanoma test’s capacity to reduce unnecessary testing https://www.clinicaltrialsarena.com/news/castle-boasts-melanoma-tests-capacity-to-reduce-unnecessary-testing/ Thu, 07 Nov 2024 11:50:16 +0000 https://www.clinicaltrialsarena.com/news/castle-boasts-melanoma-tests-capacity-to-reduce-unnecessary-testing/ A study showed that using the DecisionDx-Melanoma test resulted in a 25% reduction in unnecessary SLNB in cancer patients.

The post Castle boasts melanoma test’s capacity to reduce unnecessary testing appeared first on Clinical Trials Arena.

]]> The post Castle boasts melanoma test’s capacity to reduce unnecessary testing appeared first on Clinical Trials Arena.

]]> Intra-Cellular bolsters Caplyta data with another Phase III win https://www.clinicaltrialsarena.com/news/intra-cellular-bolsters-caplyta-data-with-another-phase-iii-win/ Wed, 06 Nov 2024 11:59:10 +0000 https://www.clinicaltrialsarena.com/news/intra-cellular-bolsters-caplyta-data-with-another-phase-iii-win/ The FDA-approved schizophrenia and bipolar disorder therapy met the primary and secondary endpoint in a Phase III “withdrawal trial”.

The post Intra-Cellular bolsters Caplyta data with another Phase III win appeared first on Clinical Trials Arena.

]]> The post Intra-Cellular bolsters Caplyta data with another Phase III win appeared first on Clinical Trials Arena.

]]> Allurion boasts over 17% weight loss with swallowable balloon device https://www.clinicaltrialsarena.com/news/allurion-boasts-over-17-weight-loss-with-swallowable-balloon-device/ Tue, 05 Nov 2024 11:06:32 +0000 https://www.clinicaltrialsarena.com/news/allurion-boasts-over-17-weight-loss-with-swallowable-balloon-device/ A study noted an average weight loss of 17.6% with Allurion’s device in patients who had no or less than 5% weight loss with GLP-1 drugs.

The post Allurion boasts over 17% weight loss with swallowable balloon device appeared first on Clinical Trials Arena.

]]> The post Allurion boasts over 17% weight loss with swallowable balloon device appeared first on Clinical Trials Arena.

]]> Biofrontera stock climbs as drug-device succeeds in Phase III skin cancer trial https://www.clinicaltrialsarena.com/news/biofrontera-stock-climbs-as-drug-device-succeeds-in-phase-iii-skin-cancer-trial/ Fri, 01 Nov 2024 11:39:11 +0000 https://www.clinicaltrialsarena.com/news/biofrontera-stock-climbs-as-drug-device-succeeds-in-phase-iii-skin-cancer-trial/ The topline results showed that Amelus and BF-RhodoLED lamp therapy met primary and secondary endpoints in the Phase III trial.

The post Biofrontera stock climbs as drug-device succeeds in Phase III skin cancer trial appeared first on Clinical Trials Arena.

]]> The post Biofrontera stock climbs as drug-device succeeds in Phase III skin cancer trial appeared first on Clinical Trials Arena.

]]> Roche’s Alzheimer’s test shows high negative predictive value https://www.clinicaltrialsarena.com/news/roches-alzheimers-test-shows-high-negative-predictive-value/ Thu, 31 Oct 2024 10:37:59 +0000 https://www.clinicaltrialsarena.com/news/roches-alzheimers-test-shows-high-negative-predictive-value/ The trial data showed that the company’s Elecsys amyloid plasma panel could rule out Alzheimer’s with a negative predictive value of 96.2%.

The post Roche’s Alzheimer’s test shows high negative predictive value appeared first on Clinical Trials Arena.

]]> The post Roche’s Alzheimer’s test shows high negative predictive value appeared first on Clinical Trials Arena.

]]> Spero’s stock slides after antibiotic flops in Phase II trial https://www.clinicaltrialsarena.com/news/speros-stock-slides-after-antibiotic-flops-in-phase-ii-trial/ Wed, 30 Oct 2024 11:45:33 +0000 https://www.clinicaltrialsarena.com/news/speros-stock-slides-after-antibiotic-flops-in-phase-ii-trial/ The company has laid off 39% of its staff as it discontinued the development of SPR720 for non-tuberculous mycobacterial pulmonary disease.

The post Spero’s stock slides after antibiotic flops in Phase II trial appeared first on Clinical Trials Arena.

]]> The post Spero’s stock slides after antibiotic flops in Phase II trial appeared first on Clinical Trials Arena.

]]> Bavarian eyes mpox vaccine label expansion to include toddlers, kickstarts Phase II trial https://www.clinicaltrialsarena.com/news/bavarian-mpox-vaccine-label-expansion-to-toddlers-starts-phase-ii-trial/ Tue, 29 Oct 2024 12:14:52 +0000 https://www.clinicaltrialsarena.com/news/bavarian-mpox-vaccine-label-expansion-to-toddlers-starts-phase-ii-trial/ The registrational trial is expected to support the approval for Bavarian’s mpox/smallpox vaccine use in children 2-11 years of age.

The post Bavarian eyes mpox vaccine label expansion to include toddlers, kickstarts Phase II trial appeared first on Clinical Trials Arena.

]]> The post Bavarian eyes mpox vaccine label expansion to include toddlers, kickstarts Phase II trial appeared first on Clinical Trials Arena.

]]> Abbott starts new trial to assess early use benefit of HeartMate 3 https://www.clinicaltrialsarena.com/news/abbott-starts-new-trial-to-assess-early-use-benefit-of-heartmate-3/ Fri, 25 Oct 2024 10:32:30 +0000 https://www.clinicaltrialsarena.com/news/abbott-starts-new-trial-to-assess-early-use-benefit-of-heartmate-3/ The study aims to identify heart failure patients who may benefit from using the company’s HeartMate3 left ventricular assist device.

The post Abbott starts new trial to assess early use benefit of HeartMate 3 appeared first on Clinical Trials Arena.

]]> The post Abbott starts new trial to assess early use benefit of HeartMate 3 appeared first on Clinical Trials Arena.

]]> Luna Diabetes trials automated wearable insulin pump https://www.clinicaltrialsarena.com/news/luna-diabetes-trials-automated-wearable-insulin-pump-2/ Thu, 24 Oct 2024 10:52:59 +0000 https://www.clinicaltrialsarena.com/?p=219533 The pivotal trial will evaluate the efficacy of the insulin device in maintaining optimal blood glucose levels in diabetes patients.

The post Luna Diabetes trials automated wearable insulin pump appeared first on Clinical Trials Arena.

]]> The post Luna Diabetes trials automated wearable insulin pump appeared first on Clinical Trials Arena.

]]>